Gamida Cell Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 31.68 million compared to USD 18.55. -Today at 07:30 am- MarketScreener
Strong start for Omisirge® launch with significant payer coverage and number of transplant centers onboarded exceeding expectations
Company continues to pursue strategic partnership to further. -Today at 07:02 am- MarketScreener
Gamida Cell Ltd. (GMDA), which recently secured FDA approval for its cell therapy Omisirge, on Monday, said that it is seeing high interest from transplant centers, exceeding its expectations.
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Gamida Cell Ltd. (NASDAQ:GMDA – Get Free Report) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 4,000,000 shares, an increase of 22.7% from the July 15th total of 3,260,000 shares. Based on an average daily volume of 2,260,000 shares, […]